European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC
EBAC was delisted on the 2nd of March, 2023.
32 hedge funds and large institutions have $43M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2021 Q2 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
33.59% more ownership
Funds ownership: 0% → 33.59% (+34%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.14M |
| 2 |
LA
Linden Advisors
New York
|
+$4.89M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$3.2M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$2.95M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$2.7M |
Top Sellers
EBAC Hedge Fund Activity: Q2 2021 in Review
32 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q2 2021, worth a combined $43M.
Buyers outnumbered sellers: 32 funds opened new EBAC positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $6.14M.
- 32 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $43M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q2 2021.
- 32 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q2 2021 and 0 closed out, a net change of +32 holders.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q2 2021 was Citadel Advisors, an estimated $6.14M added.
Based on aggregated 13F filings for Q2 2021.